DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Glembatumumab vedotin is an investigational drug.
There have been 7 clinical trials for Glembatumumab vedotin. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2013.
The most common disease conditions in clinical trials are Melanoma, Triple Negative Breast Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Celldex Therapeutics, National Cancer Institute (NCI), and University of Virginia.
There are seven US patents protecting this investigational drug and fifty-two international patents.
Recent Clinical Trials for Glembatumumab vedotin
|Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer||Celldex Therapeutics||Early Phase 1|
|Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer||University of Virginia||Early Phase 1|
Top disease conditions for Glembatumumab vedotin
Top clinical trial sponsors for Glembatumumab vedotin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Glembatumumab vedotin||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Glembatumumab vedotin||Start Trial||Compositions and methods for treating cancer||THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)||Start Trial|
|Glembatumumab vedotin||Start Trial||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|Glembatumumab vedotin||Start Trial||P97 fragments with transfer activity||biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)||Start Trial|
|Glembatumumab vedotin||Start Trial||Fragments of p97 and uses thereof||biOasis Technologies, Inc. (Richmond, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Glembatumumab vedotin||Australia||2013220749||2032-02-15||Start Trial|
|Glembatumumab vedotin||Brazil||112014019627||2032-02-15||Start Trial|
|Glembatumumab vedotin||Canada||2862476||2032-02-15||Start Trial|
|Glembatumumab vedotin||China||104114705||2032-02-15||Start Trial|
|Glembatumumab vedotin||China||108570468||2032-02-15||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|